Drug intelligence / Profile preview

IMC-002 (ImmuneCare (Suzhou) Biopharmaceuticals Co., Ltd.)

Development stage: Unknown
Lead developer: ImmuneOncia Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IMC-002 is a bispecific monoclonal antibody targeting CD20 and CD47, developed by ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. It is primarily being investigated for the treatment of autoimmune diseases, specifically Neuromyelitis Optica Spectrum Disorder (NMOSD) and Systemic Lupus Erythematosus (SLE). By targeting CD20, the drug aims to deplete B cells, while the CD47-targeting component is designed to enhance the phagocytic clearance of these cells or modulate immune responses. In clinical trials for NMOSD, it is being evaluated against mycophenolate mofetil in AQP4-antibody positive patients.

Targets

CD47 (Cluster of Differentiation 47)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on IMC-002 (ImmuneCare (Suzhou) Biopharmaceuticals Co., Ltd.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-002 (ImmuneCare (Suzhou) Biopharmaceuticals Co., Ltd.).

Explore the full profile